Octreotide’s role in the management of post-esophagectomy chylothorax
Diseases of the Esophagus · 2024
DOI: 10.1093/dote/doae011 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift Diseases of the Esophagus, 2024. Verfasst von Nathaniel Deboever und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Octreotide, Esophagectomy, Chylothorax, Length of Stay. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Mason Family Fund.
Abstract (Originalsprache)
The use of octreotide in managing intrathoracic chyle leak following esophagectomy has gained popularity in the adult population. While the benefits of octreotide have been confirmed in the pediatric population, there remains limited evidence to support its use in the adults post-esophagectomy. Thus, we performed a single-institution cohort study to characterize its efficacy. The study was performed using a prospective, single-center database, from which clinicopathologic characteristics were extracted of patients who had post-esophagectomy chyle leaks. Kaplan–Meier and multivariable Cox regression analyses were performed to investigate the effect of octreotide use on chest tube duration (CTD), hospital length of stay (LOS), and overall survival (OS). In our cohort, 74 patients met inclusion criteria, among whom 27 (36.5%) received octreotide. Kaplan–Meier revealed no significant effect of octreotide on CTD (P = 0.890), LOS (P = 0.740), or OS (P = 0.570). Multivariable Cox regression analyses further corroborated that octreotide had no effect on CTD (HR = 0.62, 95% confidence interval [CI]: 0.32–1.20, P = 0.155), LOS (HR = 0.64, CI: 0.34–1.21, P = 0.168), or OS (1.08, CI: 0.53–2.19, P = 0.833). Octreotide use in adult patients with chyle leak following esophagectomy lacks evidence of association with meaningful clinical outcomes. Level 1 evidence is needed prior to further consideration in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Förderung
- Mason Family Fund
Zitieren
APA
Deboever, N., Feldman, H., Eisenberg, M., Antonoff, M. B., Mehran, R. J., Rajaram, R., Rice, D. C., Roth, J. A., Sepesi, B., Swisher, S. G., Vaporciyan, A. A., Walsh, G. L., & Hofstetter, W. L. (2024). Octreotide’s role in the management of post-esophagectomy chylothorax. Diseases of the Esophagus. https://doi.org/10.1093/dote/doae011
Vancouver
Deboever N, Feldman H, Eisenberg M, Antonoff MB, Mehran RJ, Rajaram R, et al. Octreotide’s role in the management of post-esophagectomy chylothorax. Diseases of the Esophagus. 2024. doi:10.1093/dote/doae011
BibTeX
@article{Deboever2024,
author = {Deboever, Nathaniel and Feldman, Hope and Eisenberg, Michael and Antonoff, Mara B and Mehran, Reza J and Rajaram, Ravi and Rice, David C and Roth, Jack A and Sepesi, Boris and Swisher, Stephen G and Vaporciyan, Ara A and Walsh, Garrett L and Hofstetter, Wayne L},
title = {Octreotide’s role in the management of post-esophagectomy chylothorax},
journal = {Diseases of the Esophagus},
year = {2024},
doi = {10.1093/dote/doae011}
}
EUVIMED